Theragen Etex Co.Ltd (066700) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Theragen Etex Co.Ltd KRW 4,176, price KRW 2,265, upside +84.4%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Theragen Etex Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 1,888 KRW – 8,770 KRW · fair‑value band 3,083 KRW – 5,220 KRW · the 2,265 KRW price screens below the 4,176 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 3, 2026.
Follow Theragen Etex Co.Ltd in your weekly email
Every Wednesday you see whether Theragen Etex Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products.
Show more
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company was formerly known as Theragen Co., Ltd. and changed its name to Theragen Etex Co.,Ltd. in July 2010. Theragen Etex Co.,Ltd. was founded in 1987 and is headquartered in Seoul, South Korea.
Stock analysis
Theragen Etex Co.Ltd (066700) currently trades at 2,265 KRW, while our model-based Fair Value estimate is 4,176 KRW, implying the stock looks roughly 45.8% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 5,787 KRW per share, and 24 of the 24 models we run sit above the 2,265 KRW price.
Bear case: the Asset-Based group reads lowest at 2,539 KRW, and 0 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 3,083 KRW (bear) to 5,220 KRW (bull), the price of 2,265 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Theragen Etex Co.Ltd reported revenue of 272B KRW in FY2025 versus 167B KRW in FY2021, a compound +13.0%/yr. Reported net income was 10.6B KRW in FY2025.
Key figures
Market cap 83.1B KRW (≈ $61.9M) · P/S ratio 0.38 · Dividend yield 0.1% · Net margin 3.9% · Return on equity −3,202% · Return on assets (EBIT) 3.6% · Operating margin 2.8% · Revenue (TTM) 189B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −40% fair-value upside, at 84%, 066700 screens cheaper than that median.
Fair Value models
Bear 3,083 KRWFair Value 4,176 KRWBull 5,220 KRW
Price 2,265 KRW · Upside +84.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +10.6% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.1%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−27.4% vs 13.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 4%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+13.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +11.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 43 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Theragen Etex Co.Ltd (066700) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 4,176 KRW versus a price of 2,265 KRW, about +84% upside (undervalued).
What is the fair value of 066700?
Our model-based fair value for Theragen Etex Co.Ltd is 4,176 KRW (as of Oct 3, 2026), built from audited fundamentals. The current price: 2,265 KRW.
What is the quality score of 066700?
Theragen Etex Co.Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Theragen Etex Co.Ltd (066700)?
Our model-based price target is the fair value of 4,176 KRW (as of Oct 3, 2026) from 24 valuation models. Cautious scenario 3,083 KRW, optimistic scenario 5,220 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Theragen Etex Co.Ltd stock forecast for 2026?
Our models put fair value at 4,176 KRW, about +84% upside versus a price of 2,265 KRW (undervalued). Cautious scenario 3,083 KRW, optimistic scenario 5,220 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Theragen Etex Co.Ltd (066700)?
Theragen Etex Co.Ltd reported trailing-twelve-month revenue of about 189B KRW (latest available figure, as of Oct 3, 2026).
Does Theragen Etex Co.Ltd pay a dividend?
Theragen Etex Co.Ltd currently shows a dividend yield of about 0.14% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Theragen Etex Co.Ltd (066700)?
For today's price to be fair in a discounted-cash-flow model, Theragen Etex Co.Ltd would have to grow free cash flow by +13.7 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.7 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of 066700 use?
Our models discount Theragen Etex Co.Ltd at 12.6 %: a base by market capitalisation (micro), damped by beta 0.85, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Theragen Etex Co.Ltd that is +13.7 % per year a year over ten years, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Theragen Etex Co.Ltd (066700) delivered so far?
Over the past 5 years revenue at Theragen Etex Co.Ltd grew +13.7 % a year. The price currently implies +13.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Theragen Etex Co.Ltd (066700) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Theragen Etex Co.Ltd (+13.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Theragen Etex Co.Ltd (066700)?
The free-cash-flow yield on the price is 6.95 %: that much free cash flow Theragen Etex Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Theragen Etex Co.Ltd (066700)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Theragen Etex Co.Ltd it is 4,176 KRW per share (as of Oct 3, 2026), against a price of 2,265 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Theragen Etex Co.Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 066700 trades below its calculated fair value: price 2,265 KRW, fair value 4,176 KRW, a gap of about +84% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 066700?
No. The price is what the market pays today (2,265 KRW); the fair value is what the company's own numbers justify (4,176 KRW). For Theragen Etex Co.Ltd the two are 1,911 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Theragen Etex Co.Ltd worth?
The market values Theragen Etex Co.Ltd at about 83.1B KRW (market capitalisation, as of Oct 3, 2026). Per share that is 2,265 KRW; our models calculate a fair value of 4,176 KRW per share.
What do the bullish and bearish scenarios say about 066700?
Our models span a range for Theragen Etex Co.Ltd: cautious scenario 3,083 KRW, base 4,176 KRW, optimistic 5,220 KRW per share (as of Oct 3, 2026, price 2,265 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Theragen Etex Co.Ltd (066700)?
Balance-sheet figures for Theragen Etex Co.Ltd (as of Oct 3, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 066700 from its 52-week high?
Theragen Etex Co.Ltd trades at 2,265 KRW, about 32% below its 52-week high of 3,315 KRW and 20% above the low of 1,888 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 4,176 KRW is for.
Which stocks are comparable to Theragen Etex Co.Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Theragen Etex Co.Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 2,265 KRW, calculated fair value 4,176 KRW (+84%), Quality Score 52/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 066700 calculated?
We run Theragen Etex Co.Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,176 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Theragen Etex Co.Ltd currently trades 46 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Theragen Etex Co.Ltd (066700)?
The closing price on Oct 2, 2026 was 2,265 KRW. Our model-based fair value is 4,176 KRW, about +84% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Theragen Etex Co.Ltd right now?
The price is below even our cautious bear case (3,083 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Theragen Etex Co.Ltd
How large is the market capitalisation of Theragen Etex Co.Ltd (066700)?
The market capitalisation of Theragen Etex Co.Ltd is 83.1B KRW (≈ $61.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Theragen Etex Co.Ltd (066700)?
The price-to-sales ratio of Theragen Etex Co.Ltd is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Theragen Etex Co.Ltd (066700)?
The dividend yield of Theragen Etex Co.Ltd is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Theragen Etex Co.Ltd (066700)?
The net margin of Theragen Etex Co.Ltd is 3.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Theragen Etex Co.Ltd (066700)?
The return on equity (ROE) of Theragen Etex Co.Ltd is −3,202% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Theragen Etex Co.Ltd (066700)?
On an EBIT basis the return on assets of Theragen Etex Co.Ltd is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Theragen Etex Co.Ltd (066700)?
The operating margin of Theragen Etex Co.Ltd is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Theragen Etex Co.Ltd (066700)?
Revenue at Theragen Etex Co.Ltd is growing +13.4% versus a year earlier (3y avg +12.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Theragen Etex Co.Ltd (066700) carry?
The net debt of Theragen Etex Co.Ltd is 5.3B KRW (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Theragen Etex Co.Ltd in the live analysis
One click puts Theragen Etex Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
